- Home
- STTK vs RGS Comparison
STTK vs RGS Comparison
Compare STTK & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- RGS
- Stock Information
- Founded
- STTK 2016
- RGS 1922
- Country
- STTK United States
- RGS United States
- Employees
- STTK N/A
- RGS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- RGS Other Consumer Services
- Sector
- STTK Health Care
- RGS Consumer Discretionary
- Exchange
- STTK Nasdaq
- RGS Nasdaq
- Market Cap
- STTK 37.6M
- RGS 54.2M
- IPO Year
- STTK 2020
- RGS 1991
- Fundamental
- Price
- STTK $0.83
- RGS $23.56
- Analyst Decision
- STTK Hold
- RGS
- Analyst Count
- STTK 4
- RGS 0
- Target Price
- STTK $3.00
- RGS N/A
- AVG Volume (30 Days)
- STTK 423.3K
- RGS 9.5K
- Earning Date
- STTK 07-31-2025
- RGS 08-27-2025
- Dividend Yield
- STTK N/A
- RGS N/A
- EPS Growth
- STTK N/A
- RGS N/A
- EPS
- STTK N/A
- RGS 41.20
- Revenue
- STTK $4,606,000.00
- RGS $199,112,000.00
- Revenue This Year
- STTK N/A
- RGS N/A
- Revenue Next Year
- STTK N/A
- RGS N/A
- P/E Ratio
- STTK N/A
- RGS $0.63
- Revenue Growth
- STTK 69.65
- RGS N/A
- 52 Week Low
- STTK $0.69
- RGS $15.00
- 52 Week High
- STTK $4.99
- RGS $35.50
- Technical
- Relative Strength Index (RSI)
- STTK 38.86
- RGS 62.70
- Support Level
- STTK $0.75
- RGS $22.28
- Resistance Level
- STTK $0.85
- RGS $24.01
- Average True Range (ATR)
- STTK 0.09
- RGS 0.94
- MACD
- STTK -0.01
- RGS 0.14
- Stochastic Oscillator
- STTK 9.59
- RGS 84.06
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About RGS Regis Corporation
Regis Corp owns, franchises, and operates beauty salons throughout North America and the United Kingdom. The company's locations provide salon products and services to the mass market, including haircutting, styling, and hair coloring. The vast majority of Regis' salons are in strip malls, shopping centers, and Wal-Mart stores in North America and serve price-conscious customers. The company derives the majority of its revenue from these locations. The sale of products also contributes a relatively significant percentage of total sales. Regis also operates a smaller portfolio of premium salons across North America and the U.K. The company's majority brands include SmartStyle, Cost Cutters, and Supercuts.